Biofunctionalized Decellularized Tissue-Engineered Heart Valve with Mesoporous Silica Nanoparticles for Controlled Release of VEGF and RunX2-siRNA against Calcification

The goal of tissue-engineered heart valves (TEHV) is to replace normal and overcome the shortcomings valve replacement commonly used in clinical practice. However, calcification TEHV major bottleneck break for both workers researchers. Endothelialization plays a crucial role delaying by reducing platelet adhesion covering calcified spots. In present study, we loaded RunX2-siRNA VEGF into mesoporous silica nanoparticles investigated properties anti-calcification endothelialization vitro. Then, nanoparticle was immobilized on decellularized porcine aortic (DPAV) layer self-assembly endothelialization. Our results demonstrated that delivery vehicle good biocompatibility, stable release VEGF. hybrid exhibited low hemolysis rate promoted endothelial cell proliferation while silencing RunX2 gene expression interstitial cells, showed mechanical properties. Finally, vivo experiment could enhance valve. summary, constructed system based biofunctionalized scaffold anti-calcification.